MedTrace Logo

Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH

NCT01350960 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-11-22

No results posted yet for this study

Summary

The purpose is to study Safety and Tolerability.

Conditions

Interventions

DRUG

SPC5001

3 weekly SC injections

DRUG

Saline 0.9%

3 weekly SC injections

DRUG

SPC5001

3 weekly SC injections

DRUG

SPC5001

3 weekly SC injections

DRUG

SPC5001

3 weekly SC injections

DRUG

SPC5001

3 weekly SC injections

Sponsors & Collaborators

  • Santaris Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Koos Burggraaf, MD PhD · Centre for Human Drug Research (CHDR)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01350960 on ClinicalTrials.gov